MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dystonia: Treatment"

  • 2019 International Congress

    Alternating bilateral deep brain stimulation in the internal pallidum and subthalamic nucleus in isolated segmental dystonia: a case report

    A. Handberg, S. Jensen, AN. Høck, L. Hjermind, J. Brennum, B. Jespersen, M. Karlsborg, A. Løkkegaard (Copenhagen, Denmark)

    Objective: To present a patient with segmental dystonia and sequential bilateral deep brain stimulation (DBS) in the internal pallidum (GPi) and the subthalamic nucleus (STN).…
  • 2019 International Congress

    Use of Chemodenervation for Secondary Limb Dystonia in Parkinson’s Disease: A Single Center Experience

    V. Veerappan, M. Brodsky (Portland, OR, USA)

    Objective: To describe characteristics of patients with secondary limb dystonia in Parkinson’s Disease, types of dystonia observed, and treatment/response with chemodenervation. Background: Dystonia can be…
  • 2019 International Congress

    Long-term treatment of cervical dystonia with abobotulinumtoxinA

    A. Jochim, T. Meindl, T. Mantel, S. Zwirner, F. Castrop, B. Haslinger (Munich, Germany)

    Objective: To evaluate long-term efficacy and safety of the treatment of cervical dystonia (CD) with abobotulinumtoxinA in daily life routine in an outpatient clinic for…
  • 2019 International Congress

    Moving ear syndrome secondary to bromopride and response to botulinum toxin

    F. Sekeff-Sallem, J. Pedroso, O. Barsottini (Sao Paulo, Brazil)

    Objective: Report a case of a rare drug-induced movement disorder, the moving ear syndrome, describe its phenomenology and its treatment with botulinum toxin Background: Since…
  • 2019 International Congress

    Depression, Anxiety and Sleep Disturbances in Patients with Craniocervical Dystonias

    Z. Khayatova, Z. Zalyalova (Kazan, Russian Federation)

    Objective: This study aimed to examine whether botulinum neurotoxin (BT) treatment affects nonmotor symptoms of dystonia, particularly depression (D), anxiety (A) and sleep disturbances (SD)…
  • 2019 International Congress

    Knowledge, Attitude and Practices about Movement Disorders in India

    B. Shetty, S. Mittal, P. Kukkle (Bangalore, India)

    Objective: To understand the Knowledge about various Movement Disorders (MD) in general public and in various Movement Disorder Patients subgroups Background: The incidence of movement…
  • 2019 International Congress

    High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients

    C. Carrarini, M. Russo, F. Barbone, F. Dono, M. Rispoli, M. Onofrj, A. Thomas (Chieti, Italy)

    Objective: To assess tolerability and efficacy of high dose Safinamide treatment in Young Onset Parkinson’s Disease (YOPD) patients with dystonia and history of impulse controls…
  • 2019 International Congress

    Interleaving stimulation mode can improve better the health-related quality of life in primary generalized or segmental dystonia than standard bilateral pallidal deep brain stimulation

    N. Kovács, A. Juhasz, D. Pintér, M. Harmat, I. Balás, J. Janszky (Pécs, Hungary)

    Objective: To compare the efficacy of standard and interleaving stimulation modes in the bilateral pallidal stimulation treatment of generalized and segmental primary dystonia. Background: For…
  • 2019 International Congress

    Directional stimulation for Dystonic tremor

    I. Aviles-Olmos, M. Alegre, J. Artieda, J. Guridi, M. Rodriguez-Oroz (Pamplona, Spain)

    Objective: Is our aim to present our experience with bilateral directional thalamic DBS for DT. Background: Dystonic tremor(DT) is characterized by coexisting tremor and abnormal…
  • 2019 International Congress

    High Dose Botulinum Toxin Therapy: Safety, Benefit and Endurance of Efficacy

    S. Chiu, B. Patel, M. Burns, J. Legacy, A. Shukla, A. Ramirez-Zamora, W. Deeb, I. Malaty (Gainesville, FL, USA)

    Objective: To assess safety, therapeutic response and long-term benefit of higher dose Onabotulinum toxin A (OnaA). Background: Botulinum toxin therapy is a powerful tool for…
  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 39
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Movement disorders in chronic obstructive pulmonary disease (COPD); the effect of pulmonary disease to brain
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley